Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy

Zarotti, Cristina. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy. 2022, University of Zurich, Faculty of Medicine.

Abstract

Breast cancer is a biologically diverse disease with treatment modalities selected based on tumor stage and tumor biology. Distinct intrinsic subtypes and surrogate biomarker profiles play a major role for therapeutic decisions. Response rates to systemic and local treatments as well as the interaction with epidemiological risk factors have been validated in clinical trials and translational studies. This retrospective study addresses the question how biomarker profiles and treatment modalities in the neoadjuvant chemotherapy setting have changed during the past 15 years and what prognostic impact these changes implicate. 342 female breast cancer stage I-IV patients receiving neoadjuvant chemotherapy between 2003 and 2017 were analyzed. Overall survival (OS) was correlated with preoperative clinical stage, postoperative pathological stage, treatment modalities and tumor biology before and after chemotherapy. Two subgroups were separated using an arbitrary cut-off year at 2009/2010, due to 2010 when platinum containing regimens were first administered. Median follow-up was 54 months. 57 (17%) patients died; recurrences occurred in 103 of 342 (30%) patients. Nodal stage and intrinsic subtypes (pre- and postoperative) significantly correlated with OS (p < 0.001). Preoperative histological grading lacked prognostic power. When comparing the patient characteristics of the subgroups, we found significant difference in the following characteristics: cT, ypT, ypN, pCR and chemotherapy regimens (p < 0.001). There was no difference in OS when comparing the two subgroups. Pathological complete response (pCR) rates had a significant impact on OS and disease-free survival (DFS) in HER2+ and triple negative subtypes (p = 0.03). In multivariate analysis, high proliferation index (> 30%), clinical metastatic stage and pathological tumor stage had prognostic impact on OS (p < 0.001, p = 0.0001, p = 0.002). Clinico-pathological factors and distinct therapy regiments especially in triple negative and HER2+ subtypes have prognostic impact on pCR, OS and DFS after neoadjuvant chemotherapy.

Additional indexing

Item Type:Dissertation (cumulative)
Referees:Varga Zsuzsanna
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
UZH Dissertations
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:6 April 2022
Deposited On:09 Jan 2023 08:50
Last Modified:21 May 2024 20:14
OA Status:Green
Free access at:Related URL. An embargo period may apply.
Related URLs:https://www.zora.uzh.ch/id/eprint/211804/
https://www.nature.com/articles/s41598-021-04032-x
Download PDF  'Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy'.
Preview
  • Content: Published Version
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)

Metadata Export

Statistics

Downloads

12 downloads since deposited on 09 Jan 2023
7 downloads since 12 months
Detailed statistics

Authors, Affiliations, Collaborations

Similar Publications